Influence of RANKL and OPG in Hemophilic arthropathy

 

Yussur Falah Faraj, Fatma Abd Alhamza Obed, Baan Abdulatif Mtashar,

Nidal Karim Al-Rahal, Jaafar Hussien Kareem.

National Center of Hematology, Mustansiriyah University, Baghdad, Iraq.

*Corresponding Author E-mail: aliomran662000@yahoo.com

 

ABSTRACT:

Background: Hemophilia is a bleeding disorder characterized by recurrent bleeding, especially in joints (hemarthrosis), leading to destructive effect to the most of joint components, resulting in synovitis, osteochondral degeneration, and eventually, end-stage hemophilic arthropathy. Objective: Since few published data exist about the influence of OPG (Osteoprotegrin) and RANKL (receptor activator of nuclear factor-kappa B ligand) in haemophilic arthropathy, the present study is conducted to investigate their serum level in hemophilic patients. Methodology: This study has been carried out on Iraqi patients with hemophilia in the National Center of Hematology/Mustansiriyah University. Forty male patients involved in this study with a range of (11-44) years old, Hemophilia A affected 25 of them, while the other 15 were hemophilia B. Along with patient group, 20 healthy subjects with matched age and gender were involved as control group. The presence and severity of arthropathy among patients was determined based activated partial thromboplastin time (aPTT)) in hemophilic patients, while RANKL and OPG were determined in the serum samples of healthy and patient subjects. Result: The serum level of RANKL in Hemophilia A patients was (204.6pg/ml) is significantly (p0.001) higher than in control (164.5pg/ml) and in Hemophilia B patients was (200pg/ml). While the serum level of OPG in Hemophilia A patients was (67.2pg/ml) is significantly (p0.002) higher than in control (30.21pg /ml) and in Hemophilia B patients (48.85pg/ml). Conclusion: It can be concluded that this system RANKL, RANK, and OPG are important for the metabolism of bones.

 

KEYWORDS: Hemophilia, Hemarthrosis, RANKL, aPTT, OPG.

 

 


INTRODUCTION:

Hemophilia A and B are X-linked congenital bleeding disorders caused by a lack of or absence in coagulation factor VIII (FVIII) or factor IX (FIX). Joint bleeding is the most prevalent symptom in both adults and children with severe hemophilia.1-2 Hemophilia arthropathy commonly starts with proliferative synovitis, which is comparable to rheumatoid arthritis (RA) and osteoarthritis (OA), but may be more complex in haemophilic patients3-4. Analysis of biomarkers of joint disease can be valuable in observation the effects of joint bleeding and evaluating the therapy of such bleeds.3

 

In rheumatoid arthritis (RA) or osteoarthritis (OA) patients, a crucial pathway regulating bone biology is the

molecular triad consisting of receptor activator of nuclear factor-kB (RANK), RANK ligand (RANKL), and Osteoprotegerin which tightly controls bone turnover.5

 

RANKL binds to its receptor RANK expressed on the cell surface of osteoclast precursors, and induces osteoclast differentiation and maturation, leading to bone resorption. In the synovium, RANKL is expressed by fibroblast-like synoviocytes (type B synoviocytes) and by activated T cells, and may induce osteoclastogenesis through a mechanism enhanced by several cytokines, including TNF-α, interleukin 1 (IL-1), and IL-17, that promote both inflammation and bone resorption6-7. The secretion of RANKL by activated T cells and expression of RANKL by synovial cells in inflamed joints contribute in joint destruction in rheumatoid arthritis8. On the other hand, OPG acts as a decoy receptor for RANKL and competes for binding of RANKL to RANK, that inhibits osteoclast differentiation, activity, and survival both in vivo and in vitro.8-9

 

MATERIALS AND METHODS:

A control-based study has been carried out on Iraqi patients with hemophilia in the National Center of Hematology/Mustansiriyah University. forty male patients involved in this study with age ranged from (11-44) years, 25 of them were detected as hemophilia A, while 15 were diagnosed as hemophilia B. Along with patient group, 20 healthy subjects with matched age and gender were involved as control group. All patients were subjected to routine examinations (aPPT). From all subjects (healthy and patients), 5ml of peripheral vein blood were aspirated and divided into 2 aliquots; the first aliquot was prepared in citrate to obtain plasma for directly examination of activated partial thromboplastin time (aPTT) by using Coagulometer Stago (France) to check the coagulation process status11. While the second one was left in gel tube to obtain serum for determining serum level of the RANKL and OPG using the R and D, (USA), sandwich ELISAS kit. Data were analyzed by using Vassar Stats Web Site for Statistical Computation 12.

 

RESULT AND DISCUSSION:

Out of 40 male patients; 25 of them have hemophilia type A (HA), and the rest 15 have hemophilia type B (HB). Table-1 shows non-significant difference in the age of patients (26.03year) comparing with that of control group (27.5 year).

 

Table-1: Matching of the age between patients and control group

Age (years)

Control (n=20)

Patients (n=40)

P value

Mean

27.5

26.03

0.539

 

Table-2 shows that the serum level of RANKL in patients of HA group (204.6pg/ml) is significantly (p0.001) higher than those in control (164.155pg/ml) and in HB group (200pg/ml).

 

Table:2 The serum level of RANKL in control and hemophilic patients groups.

Groups

Number

Mean

P- value

HA

25

204.6

 

0.001

HB

15

200

Cont.

20

164.5

 

Table-3 shows the serum level of OPG in patients of HA group (67.2pg/ml) is significantly (p0.002) higher than those in control (30.21pg/ml) and in HB group (48.85 pg/ml). However Table-4 shows serum level of RANKL is highly significantly (p=0.001) with joint, knee and ankle. While, table-5 shows that serum level of RANKL doesn’t have significant positively correlation (r = 0.180, p = 0.267) with OPG and not significantly positive correlation (r = 0.14, p = 0.387) with APTT, also that serum level of OPG has no significant positively correlation (r = 0.153, p = 0.345) with APTT

 

Table-3 shows the serum level of OPG in control and hemophilic patients groups

Groups

number

mean

P-value

HA

25

67.2

 

0.002

HB

15

48.85

Con.

20

30.21

 

Table-4 shows biomarkers of RANKL with clinical sign in hemophilic patients

Clinical sign

number

mean

P-value

Knee

17

214.6

 

0.001

Elbo

14

195.1

Ankle

1

188

No

8

172.9

 

Table-5 shows correlation between biomarkers and APTT

Correlation

RANKL

OPG

APTT

RANKL

 

R = 0.180

R = 0.14

P = 0.267

P = 0.387

OPG

R= 0.180

 

R = 0.153

P=0.267

 

 

DISCUSSION:

Along with patient groups, 20 healthy subjects with matching age and gender are involved to act as control group as shown in (Table-1) that revealed non-significant difference in the age of patients (26.03.2 year) comparing with that of control group (27.5 year).

 

From Table-2 and Table-3, all biomarkers RANKL and OPG had abnormal serum levels in hemophiliaA patients compared to healthy people and hemophilia B patients, indicating that these markers have a significant role in the deterioration of joint condition in the patients of HA. Chronic inflation and delayed healing both lead to the activation of RANKL/OPG system which is responsible for extension joint damage deeper to subchondral bone. However, hemophilic arthropathy in HB patients appears less frequent because there is no chronic inflammation (i.e. normal RANKL/OPG ratio like those in healthy people.

 

In comparison to these findings, there are few published data on biomarker correlations with joint status in patients with haemophilia because haemophilic arthropathy is a systemic disease that affects only a few joints, and the severity and activity of the arthropathy is determined by the frequency and severity of bleeding events in specific joints.13 As a result, analyzing biomarkers of joint illness in haemophilia patients may be more difficult than in people with RA or OA.4

 

The RANKL and OPG values reported in this study are not consistent with those found in other recent studies. The RANK/RANKL/OPG molecular triad was compared in patients with hemophilia A and B, and it was discovered that patients with hemophilia A had lower OPG expression in synovial tissue than patients with hemophilia B, emphasizing the severity of arthropathy in the hemophilia A group14.

 

In the second and third decade of life, people who have a case of severe hemophilia, have chronic degenerative changes (hemophilic arthropathy) in one to six major joints (ankles, knees, elbows). Recurrent spontaneous intra-articular hemorrhages are the primary source of these degenerative changes15-17. The Pettersson score is a comprehensive radiologic categorization of hemophilic joints developed by the World Federation of Hemophilia to assess the degree of radiological joint degradation 18.

 

However, Table-5 shows Correlation of serum level of biomarkers (RANKL and OPG) with clinical manifestations of hemophilic patients like APTT there is non- significant and also positive correlation between RANKL and OPG.

 

CONCLUSION:

From all these findings, it can be concluded that the serum level of RANKL and OPG are much higher in HA patients than in HB. Changes in the RANK Ligand (RANK-L)/Osteoprotegerin (OPG) pathway are thought to cause bone turnover during hemarthrosis. RANK-L increases bone resorption by binding to its receptor on osteoclasts, but OPG works as a decoy receptor, preventing RANK-L from interacting with its real receptor, thereby protecting bones against excessive resorption.

 

CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation.

 

ACKNOWLEDGMENTS:

The authors would like to thank the laboratory staff in hematology and hemophelia department during hematological and all other lab studies.

 

REFERENCE:

1.      Bolton-Maggs P.H., Pasi K.J. Haemophilias A and B. Lancet. 2003; May 24;361:1801–1809. doi: 10.1016/S0140-6736(03)13405-8.

2.      Pollmann H., Richter H., Ringkamp H., Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur. J. Pediatr. 1999 DEC;158(Suppl. 3):S166–S170.doi: 10.1007/pl00014347.

3.      Van Vulpen LFD, van Meegeren MER, Roosendaal G, Jansen NWD, van Laar JM, Schutgens REG, Mastbergen SC, and Lafeber FPJG (2015). Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Osteoarthritis and Cartilage; 23: 63-69. . 2015 Jan;23(1):63-9. doi: 10.1016/j.joca.2014.09.008. Epub 2014 Sep 16.

4.      Oldenburg J, Zimmermann R, Katsarou O, Zanon E, Kellermann E, Lundin B and Ellinghaus P (2016). Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores. Haemophilia 2016 Sep;; 22: 760-764 doi: 10.1111/hae.12936. Epub 2016 Jun 24

5.      Baud’huin M, Duplomb L, Téletchéa S, Charrier C, Maillasson M, Fouassier M and Heymann D . Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem2009 Nov; 284 (46): 31704-13. doi: 10.1074/jbc.M109.030312

6.      Saidenberg-Kermanac’h N, Cohen-Solal M, Bessis N, De Vernejoul MC and Boissier MC (2004). Role of Osteoprotegerin in rheumatoid inflammation. Joint Bone Spine. 2004 Jan; 71: 9-13. doi: 10.1016/S1297-319X(03)00131-3.

7.      Vandooren B, Cantaert T, Noordenbos T, Tak PP and Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondyloarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008 Mar; ;58(3):718-29. doi: 10.1002/art.23290.

8.      Schett G, Hayer S, Zwerina J, Redlich K and Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol; 2005 Nov;1(1):47-54. doi: 10.1038/ncprheum0036.

9.      Hofbauer LC and Heufelder AE. Role of receptor activator of nuclear factor-kappa B ligand and Osteoprotegerin in bone cell biology. J Mol Med;. 2001 Jun;79(5-6):243-53. doi: 10.1007/s001090100226

10.   Holstead JD, Kong Y-Y and Penninger JM (2002). Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis; 2002 Nov;61 Suppl 2(Suppl 2):ii32-9. doi: 10.1136/ard.61.suppl_2.ii32.

11.   Levin Hillman CR, and Lusher JM (1982): Determining the sensitivity of coagulation screening reagents: a simplified method. Lab. Med. 13 (3): 162-165.

12.   Lowry R (2013): Concepts and Applications of Inferential Statistics. cited on [www.vassarstats.net].

13.   Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon M-C, and Street A. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan;19(1):e1-47. doi: 10.1111/j.1365-2516.2012.02909.x. Epub 2012 Jul 6.

14.   Melchiorre D, Linari S, Manetti M, Romano E, Sofi F, Matucci-Cerinic M, Carulli C, Innocenti M, Ibba-Manneschi L and Castaman G (2016). Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica; 2016 Feb;101(2):219-25. doi: 10.3324/haematol.2015.133462. Epub 2015 Oct 22.

15.   Rodriguez-Merchan EC (2010). Musculoskeletal complications of hemophilia. HSS J; 2009 Nov 17; 6 (1):37-42. doi: 10.1007/s11420-009-9140-9

16.   Carcao MD, van den Berg HM, Ljung R and Mancuso ME. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood; 2013 May 9;121(19):3946-52, S1. doi: 10.1182/blood-2012-11-469403. Epub 2013 Mar 12.

17.   Ozkan S, Turktas U, Ceylan FM, Guner S, Dogan A and Hiz O (2014). Clinical evaluation of the joints of patients with Hemophilia. Arch Clin Exp Surg; 2014; 3(4): 233-239: doi: 10.5455/aces.20131229032456

18.   Pettersson H, Ahlberg A, Nilsson IM (1980). A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res; 149:153‑9.

 

 

 

Received on 27.09.2021           Modified on 02.12.2021

Accepted on 12.01.2022         © RJPT All right reserved

Research J. Pharm. and Tech. 2022; 15(8):3656-3658.

DOI: 10.52711/0974-360X.2022.00612